2 results
Not approvedWill not start
The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.
Approved WMORecruiting
Primary objective:• Assess the safety of ARC Therapy at supporting the management of hemodynamic instability in participants with sub-acute or chronic Spinal Cord Injury suffering from orthostatic hypotensionSecondary objectives with clinical…